Telix Pharmaceuticals (NASDAQ:TLX) Given “Outperform” Rating at Wedbush

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “outperform” rating reissued by equities researchers at Wedbush in a report issued on Wednesday, Benzinga reports. They currently have a $22.00 price objective on the stock. Wedbush’s price target suggests a potential upside of 97.45% from the stock’s previous close.

TLX has been the subject of several other research reports. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Telix Pharmaceuticals in a research note on Tuesday, September 15th. Weiss Ratings upgraded Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, August 21st. Citigroup reiterated a “buy” rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. Finally, Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $20.50.

Telix Pharmaceuticals Price Performance

Telix Pharmaceuticals stock traded down $0.13 during midday trading on Wednesday, reaching $11.14. 295,801 shares of the stock traded hands, compared to its average volume of 217,857. The company has a 50-day simple moving average of $11.32 and a two-hundred day simple moving average of $10.44. Telix Pharmaceuticals has a 12-month low of $6.28 and a 12-month high of $13.11. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.85 and a current ratio of 2.01.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in TLX. XY Capital Ltd increased its position in Telix Pharmaceuticals by 468.0% during the second quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock worth $822,000 after buying an additional 58,739 shares during the period. Hennion & Walsh Asset Management Inc. acquired a new position in Telix Pharmaceuticals during the second quarter worth approximately $1,731,000. Bank of America Corp DE increased its position in Telix Pharmaceuticals by 523.8% during the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after buying an additional 8,423 shares during the period. Lazard Asset Management LLC increased its position in Telix Pharmaceuticals by 15.7% during the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after buying an additional 39,400 shares during the period. Finally, Private Advisor Group LLC increased its position in Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock worth $1,669,000 after buying an additional 128,070 shares during the period.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.